FDU-PB-22 is a derivative of JWH-018 that is presumed to be a potent agonist of the CB<sub>1</sub> receptor, and has been sold online as a designer drug.
FDU-PB-22 acts as a full agonist with a binding affinity of 1.19nM at CB<sub>1</sub> and 2.43nM at CB<sub>2</sub> cannabinoid receptors.
FDU-PB-22 is a controlled substance in Germany and is banned in Japan and Sweden.